All In Biotech

Drug Trial Radar · NCT07794670

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2028

Study completion May 2029

Sponsor

Lead sponsor
NewAmsterdam PharmaIndustry
Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Conditions

  • Preclinical Alzheimer's Disease

Interventions

  • Obicetrapib 10 mgDrug

    once daily 10 mg Obicetrapib tablet

  • Matching placebo tabletsDrug

    matching placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 52 in ptau 217Time frame: Baseline, Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • K2 Medical Research

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.